Vor Biopharma Inc.
VOR- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001817229
In the last 90 days, Vor Biopharma Inc. insiders filed 0 open-market purchases and 1 sale; 102 institutions reported holding it in 13F filings for Q2 2026, worth $893.0M in total; no superinvestor holds it.
Q2 2023 vs. Q1 2023
How the institutions holding Vor Biopharma Inc. changed between Q1 2023 and Q2 2023.
All holders in Q2 2023All holders in Q1 2023
| Measure | Q1 2023 | Q2 2023 | Change |
|---|---|---|---|
| Holders | 60 | 71 | +11 |
| Shares | 60.5M | 60.8M | +255.0K (+0.4%) |
| Value | $325.7M | $187.8M | −$137.9M (−42.3%) |
New holders (23)
Institutions that held Vor Biopharma Inc. at the end of Q2 2023 but not at the end of Q1 2023.
Sold out (12)
Institutions that held Vor Biopharma Inc. at the end of Q1 2023 and filed for Q2 2023 without it.
| Institution | Shares, Q1 2023 | Value, Q1 2023 |
|---|---|---|
| Janus Henderson Group PLC | 1,764,877 | $9.46M |
| Bank of Montreal | 315,063 | $1.75M |
| Qube Research & Technologies Ltd | 53,745 | $289.1K |
| Marshall Wace, LLP | 50,089 | $269.5K |
| HRT Financial LP | 41,386 | $222.0K |
| 683 Capital Management, LLC | 25,419 | $136.8K |
| Man Group plc | – | $135.2K |
| Boothbay Fund Management, LLC | 19,536 | $105.1K |
| Walleye Capital LLC | 16,463 | $88.6K |
| Diametric Capital, LP | 12,902 | $69.4K |
| Balyasny Asset Management LLC | 12,627 | $67.9K |
| D. E. Shaw & Co., Inc. | 11,478 | $61.8K |